Description of Aspire Biopharma Holdings Inc's Business Segments

The Company has identified a single reportable segment. The Chief Executive Officer, serving as the chief operating decision-maker (CODM), evaluates the Company's overall assets, operating results, and financial metrics to allocate resources and assess financial performance. Performance assessment focuses on operating expenses reported as net income and total assets as presented in the consolidated balance sheet. Key metrics reviewed include operating expenses—comprising general and administrative, research and development, and sales and marketing costs—as well as cash and cash equivalents. These metrics are monitored to manage and forecast cash flow, ensure adequate capital for operations, and maintain compliance with contractual obligations. The operating expense categories reported in the statements of operations represent the primary segment expenses regularly reviewed by the CODM.

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Composition of Aspire Biopharma Holdings Inc Revenues by Segments


Nutraceutical Products		7.94 %	of total Revenue

Q2 three months ended (Jun 30 2026)
Revenues by Business Segments	Revenues (in millions $)	% (of total Revenues)
Nutraceutical Products	0.01	7.94 %
Total	0.06	100 %

Q2 three months ended (Jun 30 2026)
Revenue Growth rates by Segment	Y/Y Revenue %	Q/Q Revenue %
Nutraceutical Products	-	-82.37 %
Total	-	88.84 %

Q2 three months ended (Jun 30 2026)
Income by Business Segments	Income (in millions $)	% (Profit Margin)
Total	-1.27	-

Q2 three months ended (Jun 30 2026)
Income Growth rates by Segment	Y/Y Income %	Q/Q Income %
Total	-	-

Annual Report on Aspire Biopharma Holdings Inc Divisions, Sales by Country


Nutraceutical Products		100 %	of total Revenue

Twelve months ended 2025
ASBP s Annual Revenue by Geography and Business Segments	Sales (in millions $)	% (of total Sales)
Nutraceutical Products	0.01	100 %
Total	0.01	100 %

Twelve months ended 2025
ASBP s Annual Income by Country and Business Segments	Income (in millions $)	% (Profit Margin)
Total	-24.48	-

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments	% Y/Y Sales Growth	% Y/Y Income Growth

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.